BAJAJ BROKING

Notification close image
No new Notification messages
card image
Amanta Healthcare Ltd IPO
Apply for the Amanta Healthcare Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

500009

AMBALALSA

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Ambalal Sarabhai Enterprises Share Price Update

As of the latest trading session, Ambalal Sarabhai Enterprises share price is currently at ₹ 32.5, which is down by ₹ -0.20 from its previous closing. Today, the stock has fluctuated between ₹ 32.13 and ₹ 32.68. Over the past year, Ambalal Sarabhai Enterprises has achieved a return of -48.99 %. In the last month alone, the return has been 0.42 %. Read More...

Investment Returns

Over 1 Month 0.42% Over 3 Months -11.83% Over 6 Months -10.21% Over 1 Year -48.99%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Ambalal Sarabhai Enterprises fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    246.80

  • P/E Ratio (TTM)

    17.13

  • Beta

    1.36

  • Book Value / share

    6.32

  • Return on equity

    2.11%

  • EPS (TTM)

    1.84

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    6.88

info icon alternate text

Ambalal Sarabhai Enterprises Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 1.64
Operating Expense 2.90
Net Profit 6.88
Net Profit Margin (%) 419.51
Earnings Per Share (EPS) 0.90
EBITDA 6.97
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1.73
Operating Expense 3.50
Net Profit -4.96
Net Profit Margin (%) -286.70
Earnings Per Share (EPS) -0.64
EBITDA -4.91
Effective Tax Rate (%) 0.40
Particulars DEC 2024 (Values in Cr)
Revenue 1.17
Operating Expense 3.86
Net Profit 8.43
Net Profit Margin (%) 720.51
Earnings Per Share (EPS) 1.10
EBITDA 8.23
Effective Tax Rate (%) -3.94
Particulars SEP 2024 (Values in Cr)
Revenue 0.00
Operating Expense 1.91
Net Profit 4.31
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) 0.56
EBITDA 4.58
Effective Tax Rate (%) 3.36
Particulars JUN 2024 (Values in Cr)
Revenue 1.14
Operating Expense 2.52
Net Profit 0.46
Net Profit Margin (%) 40.35
Earnings Per Share (EPS) 0.06
EBITDA 0.61
Effective Tax Rate (%) 6.12
Particulars MAR 2025 (Values in Cr)
Revenue 4.04
Operating Expense 11.81
Net Profit 8.24
Net Profit Margin (%) 203.96
Earnings Per Share (EPS) 1.08
EBITDA 8.52
Effective Tax Rate (%) -1.98
Particulars MAR 2024 (Values in Cr)
Revenue 3.81
Operating Expense 10.87
Net Profit 2.58
Net Profit Margin (%) 67.71
Earnings Per Share (EPS) 0.34
EBITDA 1.12
Effective Tax Rate (%) -218.51
Particulars MAR 2023 (Values in Cr)
Revenue 3.71
Operating Expense 9.12
Net Profit 4.11
Net Profit Margin (%) 110.78
Earnings Per Share (EPS) 0.54
EBITDA 4.60
Effective Tax Rate (%) 5.29
Particulars MAR 2022 (Values in Cr)
Revenue 0.13
Operating Expense 6.14
Net Profit 2.96
Net Profit Margin (%) 2276.92
Earnings Per Share (EPS) 0.39
EBITDA 3.89
Effective Tax Rate (%) 14.49
Particulars MAR 2021 (Values in Cr)
Revenue 0.00
Operating Expense 39.08
Net Profit -9.39
Net Profit Margin (%) 0.00
Earnings Per Share (EPS) -1.22
EBITDA -8.53
Effective Tax Rate (%) 0.84
Particulars MAR 2025 (Values in Cr)
Book Value / Share 18.27
ROE % 6.05
ROCE % 8.87
Total Debt to Total Equity 0.35
EBITDA Margin 10.72
Particulars MAR 2024 (Values in Cr)
Book Value / Share 17.80
ROE % 3.98
ROCE % 6.73
Total Debt to Total Equity 0.34
EBITDA Margin 9.40
Particulars MAR 2023 (Values in Cr)
Book Value / Share 17.08
ROE % 8.01
ROCE % 9.92
Total Debt to Total Equity 0.29
EBITDA Margin 12.12
Particulars MAR 2022 (Values in Cr)
Book Value / Share 15.64
ROE % 24.23
ROCE % 24.22
Total Debt to Total Equity 0.28
EBITDA Margin 22.45
Particulars MAR 2021 (Values in Cr)
Book Value / Share 9.64
ROE % 8.14
ROCE % 9.19
Total Debt to Total Equity 0.49
EBITDA Margin 11.36
Particulars MAR 2025 (Values in Cr)
Book Value / Share 6.33
ROE % 2.11
ROCE % 2.10
Total Debt to Total Equity 0.20
EBITDA Margin 81.68
Particulars MAR 2024 (Values in Cr)
Book Value / Share 5.26
ROE % 1.80
ROCE % 1.92
Total Debt to Total Equity 0.28
EBITDA Margin 81.10
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.94
ROE % 3.35
ROCE % 3.35
Total Debt to Total Equity 0.30
EBITDA Margin 143.13
Particulars MAR 2022 (Values in Cr)
Book Value / Share 4.40
ROE % 3.89
ROCE % 4.31
Total Debt to Total Equity 0.32
EBITDA Margin 3407.69
Particulars MAR 2021 (Values in Cr)
Book Value / Share 4.02
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.31
EBITDA Margin 0.00
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 11.51
Total Assets 270.04
Total Liabilities 270.04
Total Equity 139.97
Share Outstanding 76633296
Price to Book Ratio 5.54
Return on Assets (%) 1.82
Return on Capital (%) 2.62
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 32.90
Total Assets 249.52
Total Liabilities 249.52
Total Equity 136.42
Share Outstanding 76633296
Price to Book Ratio 8.65
Return on Assets (%) 2.27
Return on Capital (%) 3.13
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 28.08
Total Assets 245.74
Total Liabilities 245.74
Total Equity 130.92
Share Outstanding 76633296
Price to Book Ratio 4.15
Return on Assets (%) 4.65
Return on Capital (%) 6.57
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 28.25
Total Assets 230.50
Total Liabilities 230.50
Total Equity 119.85
Share Outstanding 76633296
Price to Book Ratio 7.93
Return on Assets (%) 20.48
Return on Capital (%) 32.46
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 31.37
Total Assets 210.05
Total Liabilities 210.05
Total Equity 73.88
Share Outstanding 76633296
Price to Book Ratio 4.39
Return on Assets (%) 13.97
Return on Capital (%) 28.91
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3.28
Total Assets 82.91
Total Liabilities 82.91
Total Equity 48.49
Share Outstanding 76633296
Price to Book Ratio 5.54
Return on Assets (%) 9.93
Return on Capital (%) 14.68
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3.01
Total Assets 81.28
Total Liabilities 81.28
Total Equity 40.29
Share Outstanding 76633296
Price to Book Ratio 8.65
Return on Assets (%) 3.17
Return on Capital (%) 5.13
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.45
Total Assets 79.74
Total Liabilities 79.74
Total Equity 37.84
Share Outstanding 76633296
Price to Book Ratio 4.15
Return on Assets (%) 5.15
Return on Capital (%) 8.33
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5.08
Total Assets 82.98
Total Liabilities 82.98
Total Equity 33.70
Share Outstanding 76633296
Price to Book Ratio 7.93
Return on Assets (%) 3.56
Return on Capital (%) 6.8
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 8.54
Total Assets 100.04
Total Liabilities 100.04
Total Equity 30.78
Share Outstanding 76633296
Price to Book Ratio 4.39
Return on Assets (%) -9.38
Return on Capital (%) -22.39
Particulars MAR 2025 (Values in Cr)
Net Income 4.83
Cash from Operations -14.39
Cash from Investing 13.26
Cash from Financing -1.52
Net change in Cash -5.88
Free Cash Flow -11.67
Particulars MAR 2024 (Values in Cr)
Net Income 6.65
Cash from Operations 12.88
Cash from Investing -5.29
Cash from Financing -2.94
Net change in Cash 0.64
Free Cash Flow 15.79
Particulars MAR 2023 (Values in Cr)
Net Income 15.17
Cash from Operations 10.14
Cash from Investing -16.78
Cash from Financing 9.08
Net change in Cash -1.97
Free Cash Flow 30.80
Particulars MAR 2022 (Values in Cr)
Net Income 54.19
Cash from Operations 15.02
Cash from Investing 5.07
Cash from Financing -19.18
Net change in Cash -2.63
Free Cash Flow 29.35
Particulars MAR 2021 (Values in Cr)
Net Income 32.54
Cash from Operations -0.34
Cash from Investing 10.08
Cash from Financing -5.84
Net change in Cash 1.95
Free Cash Flow 2.11
Particulars MAR 2024 (Values in Cr)
Net Income 0.81
Cash from Operations -3.13
Cash from Investing 3.47
Cash from Financing 0.29
Net change in Cash -0.04
Free Cash Flow -3.04
Particulars MAR 2023 (Values in Cr)
Net Income 4.33
Cash from Operations 2.30
Cash from Investing 0.60
Cash from Financing -3.76
Net change in Cash -1.63
Free Cash Flow 2.34
Particulars MAR 2022 (Values in Cr)
Net Income 3.45
Cash from Operations -7.16
Cash from Investing 20.77
Cash from Financing -16.45
Net change in Cash -3.47
Free Cash Flow -7.13
Particulars MAR 2021 (Values in Cr)
Net Income -9.46
Cash from Operations -9.98
Cash from Investing 15.76
Cash from Financing -0.31
Net change in Cash 5.02
Free Cash Flow -9.70
Particulars MAR 2020 (Values in Cr)
Net Income 15.90
Cash from Operations -4.04
Cash from Investing 4.91
Cash from Financing -0.41
Net change in Cash -0.03
Free Cash Flow -3.70
Company Name Price P/E P/B Market Cap 52 Week Low/High
BLISS GVS PHARMA LTD 159.40 15.77 1.60 1681.63 105.05 / 190.65
CIPLA LTD 1568.95 23.50 4.06 126732.58 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 328.45 9.25 2.66 966.66 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2749.15 49.18 23.86 46572.26 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMRUTAJAN HEALTH LTD 729.20 38.66 6.45 2108.16 548.05 / 838.00
ASTRAZENECA PHARMA IND LT 8937.85 105.66 29.00 22344.63 6222.35 / 10653.05
BLISS GVS PHARMA LTD 159.40 23.83 1.58 1681.63 105.05 / 190.65
ABBOTT INDIA LIMITED 32356.30 47.34 16.24 68757.14 25260.20 / 35921.55

Ambalal Sarabhai Enterprises Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
32.20 -1.55 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 32.20
  • 26 Days 33.00
  • 10 Days 32.40
  • 50 Days 34.00
  • 12 Days 32.50
  • 100 Days 36.30
  • 20 Days 32.80
  • 200 Days 40.60
32.37 PIVOT

First Support

31.53

First Resistance

33.54

Second Support

30.36

Second Resistance

34.38

Third Support

29.52

Third Resistance

35.55

RSI

48.01

ADX

12.93

MACD

-0.49

Williams % R

-60.38

Commodity Channel Index (CCI)

-10.90

Date

2025-09-02

Week

33408.00

Same Day

31115.00

Month

44032.00

1 Year

1.36

3 Year

1.06

Over 1 Month

0.42%

down

Over 1 Year

-48.99%

down

Over 3 Months

-11.83%

down

Over 3 Years

3.91%

down

Over 6 Months

-10.21%

down

Over 5 Years

8.20%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Ambalal Sarabhai Enterprises shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

Ambalal Sarabhai Enterprises corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

Ambalal Sarabhai Enterprises Share Price

Ambalal Sarabhai Enterprises Ltd., incorporated on June 5, 1978, houses a range of companies across multi-dimensional businesses. Each subsidiary is a distinct entity contributing its unique expertise and capabilities. It is one of the oldest pharmaceutical health care companies in India, and today through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. ASE's strength is to lead with cutting edge technology by creating strategic technology tie-ups and collaborative partnerships through our broad national and international networks

The Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments. It operates in two segments, pharmaceuticals and electronics. Pharmaceuticals segment is engaged in manufacture of drugs and formulations. Electronics segment is engaged in manufacture of electronics instruments and services.

In the year 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections.

During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company. During the year 1998-99, the company signed agreement with B V Chiron, Netherlands for introducing their anti-cancer drugs in India.

During the year 1999-2000, the company entered into an MoU for marketing of products of Oncology products of Chiron Corporation, USA. The Product Division essentially comprising of Sarabai Chemicals Products was transferred to the joint venture company, Sarabhai Piramal Pharmaceuticals Ltd.

In September 2008, the company acquired the manufacturing and marketing company, namely Suvik Hitek Pvt. Ltd. The Ethical Division re-launched the products of Suvik and Sarabhai Chemicals in market. Also, the company acquired Systronics (India) Pvt Ltd.

During the year 2008-09, the Oncology Division launched two new products viz. Fludagem & Xtinib. Also, the company promoted a company viz. Vovanties Laboratories Pvt Ltd, a pharmaceutical specialist with a vision to establish a state of the art manufacturing facility specializing in Novel Effervescent Drug Delivery System.

During the year 2010-11, the Company had transferred and assigned as going concern, the business undertaking of Sarabhai Chemicals Bulk Drug Division to Synbiotics Ltd and Electronics Division comprising of Systronics, Teleradand SERC to Systronics (India) Ltd with effect from October 01, 2010.

Sarabhai M Chemicals Ltd, a wholly owned subsidiary company started its Vitamin C coated products manufacturing since August 2019.

In June 2023, Asence Pharma Pvt., Ltd. a subsidiary of the Company commenced its new oncology and synthetic API plant at Ranoli, Vadodara.

Parent organization Sarabhai Ent
NSE symbol AMBASARABH
Founded 1977
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Ambalal Sarabhai Enterprises Ltd?

Answer Field

Ambalal Sarabhai Enterprises Ltd share price is for NSE ₹ 4.25 & for BSE ₹ 32.20 as on Sep 03 2025 11:48 AM.

What is the Market Cap of Ambalal Sarabhai Enterprises Ltd Share?

Answer Field

The market cap of Ambalal Sarabhai Enterprises Ltd for NSE ₹ 0.00 & for BSE ₹ 246.80 as on Sep 03 2025 11:48 AM.

What is the 52 Week High and Low of Ambalal Sarabhai Enterprises Ltd?

Answer Field

The 52 Week High and Low of Ambalal Sarabhai Enterprises Ltd for NSE is ₹ 4.60 and ₹ 0.00 and for BSE is ₹ 69.50 and ₹ 30.00.

What is 1 year return for Ambalal Sarabhai Enterprises Ltd?

Answer Field

The 1 year returns on the stock has been -48.99%.

What is the P/E Ratio of Ambalal Sarabhai Enterprises Ltd Share?

Answer Field

As on Sep 03 2025 11:48 AM the price-to-earnings (PE) ratio for Ambalal Sarabhai Enterprises Ltd share is 17.13.

What is the PB ratio of Ambalal Sarabhai Enterprises Ltd Share?

Answer Field

As on Sep 03 2025 11:48 AM, the price-to-book (PB) ratio for Ambalal Sarabhai Enterprises Ltd share is 6.32.

How to Buy Ambalal Sarabhai Enterprises Ltd Share?

Answer Field

You can trade in Ambalal Sarabhai Enterprises Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Ambalal Sarabhai Enterprises Ltd Share on Bajaj Broking App?

Answer Field

To buy Ambalal Sarabhai Enterprises Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Ambalal Sarabhai Enterprises Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91